IVZ:NYSEInvesco Ltd Analysis
Data as of 2026-04-11 - not real-time
$23.58
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Invesco Ltd. (IVZ) trades at $23.58, roughly 19% below its DCF‑derived fair value of $26.97, and offers a 3.56% dividend yield with a 56% payout ratio. The forward P/E of 8.1 is less than half the asset‑management industry average of 17.1, reinforcing the stock’s undervalued label in recent analyst screens. Technicals are mixed: the 20‑day SMA sits just above price, the MACD histogram is positive indicating a slight bullish bias, while RSI at 46 suggests no immediate overbought pressure; support sits near $21.82 and resistance at $24.79. Volatility remains elevated at over 40% (30‑day) and beta is high at 1.67**, reflecting sensitivity to market swings. Recent news highlights include its inclusion in a “most undervalued financial stocks” list, praise for dividend attractiveness, the launch of the Invesco QQQ Equal Weight ETF, and a downgrade to Hold with a $21 target, while a competing BlackRock Nasdaq‑100 ETF filing adds short‑term competitive pressure. Despite these headwinds, the firm reported a modest 1.2% AUM growth and is expanding into private real estate, suggesting a resilient earnings outlook ahead of the Q1 2026 results release on April 28.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Upcoming Q1 earnings release (April 28) may clarify profitability trends
- Recent downgrade to Hold and competitive pressure from BlackRock's Nasdaq‑100 ETF
- Price near technical support with modest upside potential
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF upside of ~19% and analyst consensus Buy with median target $27
- Attractive dividend yield and sustainable payout
- Expansion into private real estate and new ETF offerings driving AUM growth
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Consistent cash flow generation and solid free cash flow
- Low valuation multiples relative to industry peers
- Diversified product suite and global investment platform supporting steady earnings
Key Metrics & Analysis
Financial Health
Revenue Growth6.20%
Profit Margin-4.42%
P/E Ratio8.1
ROE-1.22%
ROA2.60%
Debt/Equity17.16
P/B Ratio1.1
Op. Cash Flow$1.5B
Free Cash Flow$745.7M
Industry P/E17.1
Technical Analysis
TrendNeutral
RSI46.1
Support$21.82
Resistance$24.79
MA 20$23.61
MA 50$25.02
MA 200$23.58
MACDBullish
VolumeIncreasing
Fear & Greed Index87.09
Valuation
Fair Value$26.97
Target Price$28.09
Upside/Downside19.13%
GradeUndervalued
TypeValue
Dividend Yield3.56%
Risk Assessment
Beta1.67
Volatility40.20%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.